血必净注射液治疗全身炎症反应综合征临床疗效分析

目的：探讨血必净注射液治疗全身炎症反应综合征（SIRS）的疗效.方法：选取我院收治的56例SIRS患者为研究对象,随机分为对照组和治疗组,每组28例,对照组给予常规治疗,观察组在此基础上联合采用血必净治疗.结果：连续治疗7d后,观察组在T、RR、HR、CRP、WBC指标方面均显著优于对照组（P〈0.05）;观察组患者MODS发生率为14.3%,病死率为3.8%,对照组则分别为25.0%、42.9%（P〈0.05）.结论：血必净注射液能有效中断失控的全身炎症反应,降低MODS发生率和死亡率,可以大力推广应用.

A clinical analysis of treating systemic inflammatory response syndrome withthe Xue bijing injection

Objective： To investigate clinical effects of the Xuebijing injection on systemic inflammatory response syndrome （SIRS）.Methods： 56 patients were randomly divided into treatment group and control group, 28 cases for each, the control group was given conventional treatment, and the observation group was given the Xuebijing injection. Results： T, RR, HR, CRP, WBC in the observation group were significantly better （P〈0.05）; in the observation, incidence of MODS was 14.3 %, mortality was 3.8%; those were 25.0% and 42.9% in the control respectively （P〈0.05）. Conclusion： The Xuebijing injection can interrupt uncontrolled systemic inflammatory response,reduce the incidence of MODS and mortality, and is worthy of clinical application.